TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03992326
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.
Study: NCT02929576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782897
Drug: Immunoglobulin Therapy
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
Study: NCT00859755
Drug: ARRY-403, glucokinase activator; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, escalating
Study: NCT00859755
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01815957
Drug: Rnalozine
Approvals — FDA: no, EMA: no, PMDA: no
Description: . After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
Study: NCT01636141
Drug: OLT1177 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
Study: NCT01636141
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00014534
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/ sq m IV
Study: NCT00273364
Drug: Standard treatment with a conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
Study: NCT03154619
Drug: 0.1% TR 987
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR 987 0.1%
Study: NCT03154619
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
Study: NCT02242877
Drug: Telmisartan combined with hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01837316
Drug: FF/VI 100/25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
Study: NCT01837316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: First strip: Inhalation powder of lactose
Study: NCT02320019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching YH14618
Study: NCT02320019
Drug: YH14618
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01157481
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy
Study: NCT02692157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Neurokinin 1,3 antagonist
Study: NCT00989729
Drug: Physiological Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
Study: NCT03218722
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
Study: NCT00910715
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 100 mg bid, 10 days
Study: NCT00910715
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 100 mg bid, 15 days
Study: NCT00910715
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: control subjects without a history of Lyme borreliosis
Study: NCT00073905
Drug: capecitabine plus gemcitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine plus gemcitabine
Study: NCT01824303
Drug: LiRIS 400 mg
Normalized name: IRIS TENAX
Approvals — FDA: no, EMA: no, PMDA: no
Description: LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
Study: NCT02267655
Drug: inhaled Nitric Oxide - 30 mcg/kg IBW/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
Study: NCT02267655
Drug: inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
Study: NCT02267655
Drug: inhaled nitric oxide 75 mcg/kg IBW/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
Study: NCT01513291
Drug: MK-6096
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
Study: NCT01513291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 2 tablets, orally, once daily
Study: NCT03127124
Drug: NANT-008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI)
Study: NCT03127124
Drug: Fluorouracil Injectable Product
Normalized name: fluorouracil Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione.
Study: NCT03127124
Drug: Avastin Injectable Product
Normalized name: Avastin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized monoclonal IgG1 antibody
Study: NCT03127124
Drug: Leucovorin Calcium Injection
Normalized name: Leucovorin Calcium Injection
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N -\[p -\[\[\[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1).
Study: NCT03127124
Drug: Eloxatin Injectable Product
Normalized name: Eloxatin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum.
Study: NCT04307186
Drug: Gadoquatrane (BAY1747846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV injection, single dose
Study: NCT02106468
Drug: Omega-3 soft capsules 1000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
Study: NCT04394351
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching formulation and regimen (depending on the weight tier) as dupilumab without the active substance
Study: NCT00828646
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, once daily, 14 days
Study: NCT00824317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01068327
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01068327
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02370121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
Study: NCT00967408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitative treatment + oral inactive placebo for 6 months
Study: NCT02483247
Drug: BBI503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
Study: NCT02483247
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m\^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
Study: NCT02483247
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m\^2 body surface area is administered intravenously once every three weeks (21-days).
Study: NCT00647712
Drug: Depakote ER® Tablets 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg, single dose fasting
Study: NCT02738775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683759
Drug: 5-Aminosalicyclic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage is as instructed by patient's physician
Study: NCT04745143
Drug: Placebo Cap
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo as a comparator
Study: NCT03228238
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin calcium 10mg
Study: NCT03228238
Drug: Standard medication for variant angina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Channel blocker or NG
Study: NCT01018264
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
Study: NCT02503605
Drug: Biosimilar recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
Study: NCT02503605
Drug: Urinary FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled ovarian stimulation with 150 IU/day urinary FSH
Study: NCT03063541
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg daily as one tablet
Study: NCT00367263
Drug: Alvesco (Ciclesonide) 160 ug/day
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002884
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04441450
Drug: [14C]ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg suspension containing 100μCi of \[14C\]ICP-022
Study: NCT02316197
Drug: MSC2490484A (M3814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received MSC2490484A capsules at escalated dose from 100 mg to 400 mg orally from Day 1 to Day 21 of each treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, and/or occurrence of any criterion for withdrawal from study or M3814.
Study: NCT01859715
Drug: Hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
Study: NCT00945919
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid Opioid rotation/titration
Study: NCT00128180
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01251484
Drug: BIBF1120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet 200 mg twice daily until progression
Study: NCT05337878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelacarsen-matching placebo administered by SC injection.
Study: NCT01584947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge taken three times a day for two weeks
Study: NCT02644967
Drug: IMO-2125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
Study: NCT00782652
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
Study: NCT00673452
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
Study: NCT03069027
Drug: saline adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03069027
Drug: Xylocaine, adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03717038
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.
Study: NCT01800071
Drug: MVA-EBNA1/LMP2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03477500
Drug: Cyclophosphamide and ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoetic stem cell transplantation
Study: NCT02287415
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265811
Drug: Folfox
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00018356
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02928328
Drug: Pain modulation
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
Study: NCT02969928
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of Clarithromycin 500mg bid for 7 days
Study: NCT02404363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets 75 mg for six months:~In case of treatment with aspirin \< or = 75 mg/d or prophylactic LMWH --\> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --\> placebo 150 mg/d x 7days then 75mg/d
Study: NCT03609294
Drug: Treatment A (Fimasartan, Linagliptin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of Fimasartan and Linagliptin
Study: NCT01132521
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
Study: NCT02258152
Drug: SYN120
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
Study: NCT02258152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo QD
Study: NCT02629146
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02629146
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02537080
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
Study: NCT04485481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching single dose placebo
Study: NCT04485481
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching multiple dose placebo
Study: NCT02100267
Drug: Methacholine Chloride (SK-1211)
Normalized name: Methacholine Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
Study: NCT01479634
Drug: Standard ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
Study: NCT01479634
Drug: Study-Provided ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study provided drugs:~1. Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate \[TDF\] and emtricitabine \[FTC\]) PLUS~2. Efavirenz \[EFV\]
Study: NCT00402389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four capsules will be taken daily for 8 weeks.
Study: NCT00211081
Drug: Spironolactone (drug)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
Study: NCT01788501
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
Study: NCT01503489
Drug: Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
Study: NCT02772016
Drug: Colla corii asini
Normalized name: CORID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of Colla corii asini in powder form daily for 4 weeks
Study: NCT00956150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo TID PO x 10 days
Study: NCT00678691
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01689896
Drug: Testosterone Gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01689896
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03192150
Drug: ISV-305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days
Study: NCT00219934
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART therapy
Study: NCT03623737
Drug: neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiation:~1. Radiation: 180cGy/fraction, once daily, 5 days a week, to a total of 4,500cGy.~2. Chemotherapy: Arm A or Arm B Surgery: esophagectomy and 3-fields lymph node dissection
Study: NCT01890200
Drug: TCM-700C
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An add-on drug to conventional treatment of Hepatitis C
Study: NCT01890200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, without acting ingredient.
Study: NCT01142258
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive or inert pill which will be used as a comparator
Study: NCT01485861
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally once daily
Study: NCT01485861
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orally bid
Study: NCT02665728
Drug: BLI400 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00705575
Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
Study: NCT01611571
Drug: placebo Risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly placebo of Risedronic Acid
Study: NCT03296163
Drug: EU-approved Avastin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg IV every 3 weeks on Day 1
Study: NCT04055194
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnant women with symptomatic placenta previa with previous bleeding attacks will receive placebo tablets four times daily till delivery.
Study: NCT00354224
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03844451
Drug: Bupivacaine and Epinephrine
Normalized name: Bupivacaine and epinephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the start of the procedure, 0.5% bupivacaine and 1:200,000 epinephrine as a surgical field block.
Study: NCT00702130
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pravastatin 40mg per os once daily
Study: NCT00079274
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00079274
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00079274
Drug: Locally Directed Therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
Study: NCT00226616
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01683292
Drug: Inhaled VR040
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01683292
Drug: Placebo for VR040
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm
Study: NCT00843154
Drug: Standard chronic heart disease therapy
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
Study: NCT02187315
Drug: induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03056690
Drug: ASP0819
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT03056690
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT01585766
Drug: MEDI-551 60 MG-SC
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received SC injection of 60 mg MEDI-551 on Day 1.